




ELSEVIER

Fluorine and Health



*Molecular Imaging, Biomedical
Materials and Pharmaceuticals*



EDITED BY

Alain Tressaud & Günter Haufe

Q58
F646

Fluorine and Health

Molecular Imaging, Biomedical Materials and Pharmaceuticals

Edited by

Alain Tressaud

ICMCB-CNRS

University of Bordeaux I

33608 Pessac Cedex,

France

Günter Haufe

Organisch-Chemisches Institut,

Westfälische Wilhelms-Universität Münster

Münster,

Germany



ELSEVIER

Amsterdam • Boston • Heidelberg • London • New York • Oxford • Paris
San Diego • San Francisco • Singapore • Sydney • Tokyo



E2009003665

Elsevier

Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands
Linacre House, Jordan Hill, Oxford OX2 8DP, UK

First edition 2008

Copyright © 2008 Elsevier B.V. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at <http://elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-444-53086-8

For information on all Elsevier publications visit our website at books.elsevier.com

Printed and bound in Hungary

08 09 10 11 12 10 9 8 7 6 5 4 3 2 1

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER

BOOK AID
International

Sabre Foundation

Fluorine and Health

**Molecular Imaging,
Biomedical Materials and
Pharmaceuticals**

Front cover illustrations:

- ^{18}F FDG PET scans depicting glucose metabolism in a monozygotic twin pair and in a control subject. Note the clear reduction in ^{18}F FDG uptake especially in temporo-parietal areas in the co-twin having Alzheimer disease (left) and similar, but less pronounced, reduction in same brain areas in the cognitively healthy co-twin (middle), as compared to the uptake in a control subject (right) [Image by courtesy of K. Någren and J.O. Rinne, Turku, PET Centre, Finland and cf. chapter 2 in this book].

-X-ray derived structure of the fluorinase showing the full structure as a hexamer (dimer of trimers) [cf. chapter 18 by Hai Deng, D. O'Hagan et al. in this book].



Contributors

Charles Baquey	379
Jean-Pierre Bégué	553
X. Benouaich	407
Danièle Bonnet-Delpon	553
Christèle Combes	279
Weina Cui	197
Beata Czarnecka	333
Hai Deng	761
Frédéric Dollé	3
Joachim H. Dresp	421
Christophe Drouet	279
Marie-Christine Durrieu	379
Andreas Faust	85
Robert G. Guidoin	379
Günter Haufe	xi,85,661
Ken Herrmann	141
Fang-Lu Huang	761
Christian Jäckel	737
Kenneth L. Kirk	661
Beate Kokschr	737
Klaus Kopka	85
Marie Pierre Krafft	447
Bernd Joachim Krause	141
Bertrand Kuhnast	3
Marie-Claire Lasne	3
Ralph P. Mason	197
A. Mathis	407
Yasushi Matsumura	623
Dirk-Henning Menz	421
Kjell Någren	67
James H. Naismith	761
John W. Nicholson	333
David O'Hagan	761
V. Pagot-Mathis	407
Maja Ponikvar	487

J. C. Quintyn	407
Christian Rey	279
I. Rico-Lattes	407
Jean G. Riess	447
Juha O. Rinne	67
Dirk Roeda	3
Mario Salviczek	737
Michael Schäfers	85
Otmar Schober	85
Hocine Sfihi	279
Jonathan B. Spencer	761
Alain Tressaud	xi
Stefan Wagner	85
John T. Welch	699
Shinichi Yoshida	661
Jian-Xin Yu	197
Dawen Zhao	197
Xiaofeng Zhu	761

Preface

Recently it was stated that fluorine chemistry is experiencing a renaissance due to the multifaceted reactivity of fluorinating reagents and the outstanding, and sometimes unexpected, properties of compounds containing fluorine. The benefits of these compounds for our society are evident in many fields. Particularly the last two decades have witnessed a spectacular growth of interest in selectively fluorinated molecular compounds. Both low molecular weight molecules and polymers, as well as highly sophisticated materials, are crucial in manifold aspects of medicinal monitoring and health care. This book is designed to acknowledge the extraordinary impact of fluorinated compounds to the general topic of *Fluorine and Health*. The involved subjects are organized in three thematic parts devoted to *Molecular Imaging*, *Biomedical Materials*, and *Pharmaceuticals*.

The first chapters are focused on the key position in biochemical and medicinal analytics of both partially fluorinated low molecular weight compounds labeled with natural ^{19}F -isotope for Magnetic Resonance Imaging (MRI) and tracer molecules labeled with radioactive $[^{18}\text{F}]$ -isotope for Positron Emission Tomography (PET). The selective synthesis of molecules exhibiting specific properties or physiological effect constitutes the backbone of every medicinal application of fluorinated compounds. Consequently, the methodology for introducing fluorine itself or fluorinated groups into organic skeletons is largely developed in most chapters. Sensitive PET for high resolution molecular *in vivo* imaging requires the preparation of positron-emitting radiotracers. For this purpose, $[^{18}\text{F}]$ -labeled probes are becoming increasingly prerequisite molecules, due to their adequate physical, physiological, and nuclear characteristics, particularly the relatively long half-life of the $[^{18}\text{F}]$ -isotope of ~ 110 min as compared to other light positron-emitting isotopes such as $[^{11}\text{C}]$ (20 min), $[^{13}\text{N}]$ (10 min), or $[^{15}\text{O}]$ (2 min). Thus, the development of selective and fast synthetic methods for fluoroorganic compounds is an important issue.

The PET technique is particularly useful for *in vivo* imaging in oncology, neurology and in cardiology. PET and PET/CT (computed tomography) using $[^{18}\text{F}]$ -labeled compounds such as 2-deoxy-2- $[^{18}\text{F}]$ fluoro-D-glucose ($[^{18}\text{F}]$ FDG) are becoming essential as *in vivo* imaging methods in oncological diagnostics, tumor prognosis and therapy monitoring. Moreover, innovative and more specific new $[^{18}\text{F}]$ -tracers for molecular imaging of tumor biology are highlighted in the

framework of their clinical value. Brain imaging using PET is one of the important new tools in monitoring of different neuronal diseases such as Alzheimer's disease, the devastating brain disorder of elderly humans. A number of recently developed [^{18}F]-radiopharmaceuticals have a unique potential for the study of several brain systems of clinical importance. Moreover, the molecular imaging of cardiovascular diseases with [^{18}F]-PET is of great clinical interest, offering the opportunity to investigate noninvasively the cardiovascular physiology and pathophysiology *in vivo* and to contribute to the diagnosis and treatment of diseases having the highest mortality in the industrialized countries. Similarly, the ^{19}F nucleus provides a powerful tool for spectroscopic studies and particularly for MRI, due to its high NMR sensitivity and the fact that there is essentially no background signal in the body. Furthermore, fluorine NMR allows multiple compounds to be examined simultaneously because of the very large chemical shift range of about 300 ppm.

The manifold facets of fluorinated biomaterials are illustrated by examples ranging from inorganic ceramics to perfluorinated organic molecules. Fluorine is an essential trace element in bone mineral, dentine and tooth enamel and is considered as one of the most efficient elements for the prophylaxis and treatment of dental caries. Fluoride-based treatments have been shown indeed to ensure populations developing and maintaining sound dental health. In particular, fluoride ion has an effect on the demineralization/remineralization equilibrium that exists at the tooth surface, shifting it back in favor of remineralization. Fluoride-containing bioactive glasses and ceramics have been found to have an important role in bone repairing materials. Resin-modified glass-ionomers and compomers are dental restoratives which allow fluoride releasing, thus bringing a greater availability and efficiency of the element. Highly diluted fluoridation of drinking water, fluoridated table salt, dentifrices, topical gels, varnishes and mouth-rinses are other types of possible ways to improve dental health, provided small amounts of fluoride are administered.

Another field of application of fluorinated biomaterials is connected to lesions or evolving disease pathology of blood vessels. In particular, arteries may become unable to insure an adequate transport of the blood to organs and tissues. Polytetrafluoroethylene (PTFE) and expanded e-PTFE are the preferred materials for vascular prostheses. The interactions of blood cells and blood plasma macromolecules with both natural and artificial vessel walls are discussed in terms of the mechanical properties of the vascular conduit, the morphology, and the physical and chemical characteristics of the blood contacting surface.

Conversely, the role of perfluorocarbons for oxygen transport and *in vivo* delivery is investigated. In addition to possible use as temporary blood substitute, these fluorocarbon molecules can be applied as respiratory gas carriers, for instance as lung surfactant replacement compositions for neonates and possibly for the treatment of acute respiratory distress syndrome for adults. Another

important issue concerns the applications of highly fluorinated liquids in ophthalmology. Retinal detachment, a disease that can result in blindness, is treated by performing in retinal scar around the tear and maintaining the retina in contact. For this purpose, dense fluorinated liquids are used in pure form or as mixtures with silicone oils. The state of the art of the application of these highly fluorinated liquids in ophthalmology and their biocompatibility and toxicity is discussed. Prospects concerning future applications of these molecules are also considered. Finally, the various origins of human exposure to fluoride species are detailed, together with invaluable recommendations for adequate intake of fluoride, methods for assessing exposure, and discussion of the benefits and drawbacks (fluorosis) of fluoride intake. These investigations should bring a better understanding of the effect of fluoride species on living organisms.

The main focus of the third part is the synthesis of medicinally relevant fluorinated molecules and their interaction with native proteins. New molecules fluorinated in strategic position are crucial for the development of pharmaceuticals with desired action and optimal pharmacological profile. Among the hundreds of marketed active drug components, there are more than 150 fluorinated compounds. It starts by illustrating how the presence of fluorine atoms modifies the properties of a bioactive compound at various biochemical steps, and possibly facilitates its emergence as a pharmaceutical agent. Recent advances in the development of fluorinated analogues of natural products led to new pharmaceuticals such as fluorinated nucleosides, alkaloids, macrolides, steroids, and amino acids.

More specifically, it is detailed how fluorine substitution of specific positions in prostaglandins and thromboxanes, locally produces hormones with a broad variety of biological functions, affecting not only the molecular conformation but also the drug–receptor complex through a contribution of fluorine to the nature and strength of the interaction. Amine oxidases have critically important functions in organisms for efficient deactivation of very potent biogenic amines and hence come into the focus for therapeutic intervention. These points include the development of selective inhibitors, tools for studies of reaction mechanisms, radiotracers for PET imaging, and of medicinal agents. Synthesis and biochemical evaluation of two types of medicinally relevant enzymes, the flavin-dependent monoamine oxidases (MAO) A and B, and the copper-containing amine oxidases (CAO) are highlighted.

The potential utility of peptides as therapeutics with clinical applications is limited by its metabolic instability or poor transmembrane mobility. Consequently, the preparation of metabolically stable peptide analogs that can either mimic or block the function of natural peptides or enzymes is an important area of medicinal chemistry research. Synthesis of fluoroolefin amide isosteres, its incorporation in peptidomimetics, and the influence of that isosteric substitution on the inhibition of several enzymes such as peptidyl prolyl isomerases, dipeptidyl peptidase IV, and thermolysin is described. Moreover, protein folding and activity

depend on a multitude of molecular interactions. Nevertheless, even interactions of single fluorinated amino acids can highly affect polypeptide folding. Though, the metabolic and structural stability of peptides and proteins containing fluorine substitutes have been studied extensively recently, the *de novo* design of relevant target molecules requires a detailed knowledge of molecular interactions introduced by the fluorine atom. Systematic investigation of different fluorinated amino acids incorporated in a model peptide system based on the α -helical coiled coil motive within a hydrophobic and hydrophilic protein environment led to new insights of protein structure.

Finally, recent developments on research into the first C–F bond forming enzyme are summarized. The fluorinase enzyme isolated from *Streptomyces cattleya* catalyzes the formation of 5'-fluoro-5'-deoxyadenosine from S-adenosyl-L-methionine and fluoride. The substrate specificity and subsequent transformation of the fluorinated nucleoside to fluoroacetic acid and to fluoro threonine are discussed.

While conceiving the present book, we had outstanding support by a number of colleagues. We would like to express our deep gratitude to the Associate Advisors: B. Ameduri, P. Atkins, J. Knowles, T. Nakajima, M. Pontié, R. Syvret, S. Tavener, and J. Winfield for their encouraging advice and very helpful suggestions. In particular, we are deeply indebted to all the authors who compiled a truly excellent collection of important current facts connected to *Fluorine and Health*. We believe that the particular chapters constituting this book highlight the outstanding role of fluorine in different areas of medicinal monitoring and health care.

Alain Tressaud and Günter Haufe
Pessac and Münster, October 2007

CONTENTS

Contributors	ix
---------------------	----

Preface	xi
----------------	----

Part I: Molecular Imaging

1. Fluorine-18 Chemistry for Molecular Imaging with Positron Emission Tomography	3
<i>Frédéric Dollé, Dirk Roeda, Bertrand Kuhnast, and Marie-Claire Lasne</i>	
2. Application of ^{18}F -PET Imaging for the Study of Alzheimer's Disease	67
<i>Kjell Någren and Juha O. Rinne</i>	
3. ^{18}F -Labeled PET-Tracers for Cardiological Imaging	85
<i>Klaus Kopka, Stefan Wagner, Michael Schäfers, Andreas Faust, Otmar Schober, and Günter Haufe</i>	
4. [^{18}F]-Labeled PET and PET/CT Compounds in Oncology	141
<i>Ken Herrmann and Bernd Joachim Krause</i>	
5. Non-Invasive Physiology and Pharmacology Using ^{19}F Magnetic Resonance	197
<i>Jian-Xin Yu, Weina Cui, Dawen Zhao, and Ralph P. Mason</i>	

Part II: Biomedical Materials

6. Fluoride-Based Bioceramics	279
<i>Christian Rey, Christèle Combes, Christophe Drouet, and Hocine Sfihi</i>	
7. Fluoride in Dentistry and Dental Restoratives	333
<i>John W. Nicholson and Beata Czarnecka</i>	
8. Fluorinated Biomaterials for Cardiovascular Surgery	379
<i>Charles Baquey, Marie-Christine Durrieu, and Robert G. Guidoin</i>	

9. Fluorinated Molecules in Eye Surgery: Experimental and Clinical Benefit of a Heavy Silicone Oil Oxane Hd® (Mixture of Silicone Oil and RMN3 Fluorine Olefin) in the Treatment of Retinal Detachment 407
I. Rico-Lattes, J. C. Quintyn, V. Pagot-Mathis, X. Benouaich, and A. Mathis
10. Biocompatibility of Highly Fluorinated Liquids Used in Ophthalmic Surgery 421
Dirk-Henning Menz and Joachim H. Dresch
11. Perfluorochemical-Based Oxygen Therapeutics, Contrast Agents, and Beyond 447
Marie Pierre Krafft and Jean G. Riess
12. Exposure of Humans to Fluorine and Its Assessment 487
Maja Ponikvar

Part III: Pharmaceuticals

13. Biological Impacts of Fluorination: Pharmaceuticals Based on Natural Products 553
Jean-Pierre Bégué and Danièle Bonnet-Delpon
14. Synthesis and Pharmacological Properties of Fluorinated Prostanoids 623
Yasushi Matsumura
15. Synthesis and Biochemical Evaluation of Fluorinated Monoamine Oxidase Inhibitors 661
Kenneth L. Kirk, Shinichi Yoshida, and Günter Haufe
16. Fluoroolefin Dipeptide Isosteres: Structure, Syntheses, and Applications 699
John T. Welch
17. Molecular Interactions of Fluorinated Amino Acids in a Native Polypeptide Environment 737
Mario Salwiczek, Christian Jäckel, and Beate Koksche

18. Biological Fluorination in *Streptomyces cattleya*: The Fluorinase 761
Hai Deng, Fang-Lu Huang, James H. Naismith,
David O'Hagan, Jonathan B. Spencer, and Xiaofeng Zhu

Subject Index 779

Colour Plate Section at the end of this book

SECTION 1

Molecular Imaging

CHAPTER 1

Fluorine-18 Chemistry for Molecular Imaging with Positron Emission Tomography

Frédéric Dollé,^{1,*} Dirk Roeda,¹ Bertrand Kuhnast,¹
and Marie-Claire Lasne²

¹*Institut d'Imagerie Biomédicale, CEA, Service Hospitalier Frédéric Joliot,
4 Place du Général Leclerc, F-91401 Orsay cedex, France*

²*CNRS, Département Chimie, 3 Rue Michel Ange, 75794 Paris cedex, France*

Contents

1. Introduction	4
2. The radionuclide fluorine-18 and some general considerations concerning short-lived positron emitters	5
2.1. The position of fluorine-18 among short-lived positron emitters for PET	5
2.2. Design of radiotracers and radiopharmaceuticals labelled with a short-lived positron emitter: The case of fluorine-18	7
2.3. Challenges in radiochemistry with short-lived positron emitters, including fluorine-18	8
2.4. Fluorine-18 production	10
2.5. Methods of radiofluorination	11
2.6. Early fluorine-18-labelled precursors	12
3. Electrophilic radiofluorination	14
3.1. Preparation of electrophilic fluorination reagents	15
3.1.1. Molecular [¹⁸ F]fluorine	15
3.1.2. Trifluoromethyl [¹⁸ F]hypofluorite	15
3.1.3. Acetyl [¹⁸ F]hypofluorite	15
3.1.4. Perchloryl [¹⁸ F]fluoride	16
3.1.5. Xenon di[¹⁸ F]fluoride	16
3.1.6. 1-[¹⁸ F]Fluoro-2-pyridone	17
3.1.7. <i>N</i> -[¹⁸ F]Fluoropyridinium triflate	17
3.1.8. <i>N</i> -[¹⁸ F]Fluoro- <i>N</i> -alkylsulphonamides	17
3.1.9. Bromo [¹⁸ F]fluoride	18
3.2. Fluorination of double-bond structures	18
3.2.1. Fluorination of alkenes	18
3.2.2. Fluorination of enol structures	21
3.3. Fluorination of carbanions	22
3.4. Fluorination of aromatic rings (other than via carbanions)	23
3.4.1. Fluorodehydrogenation	24
3.4.2. Fluorodemetalation	25

*Corresponding author. Tel.: +33-(0)1-69-86-77-04; Fax: +33-(0)1-69-86-77-49;
Email: frederic.dolle@cea.fr